Yıl: 2020 Cilt: 55 Sayı: 2 Sayfa Aralığı: 95 - 102 Metin Dili: Türkçe DOI: 10.14744/TurkPediatriArs.2020.20270 İndeks Tarihi: 19-08-2020

Çocuklarda SARS-CoV-2 enfeksiyonu

Öz:
İki bin on dokuz Aralık ayı itibariyle Çin’in Wuhan bölgesindenbaşlayarak, tüm dünyayı etkisi altına almış olan bir RNA virüsüolan SARS-CoV-2 tüm yaş gruplarını olduğu gibi çocukları da etkilemektedir. İki bin yirmi Mart ayı itibariyle ülkemizde de ilk olgulargörülmeye başlanmıştır. Damlacık ve bu damlacıkların kontamineettiği yüzeylerden temas yoluyla yayılan SARS-CoV-2, çocuklara genel olarak temaslı oldukları erişkinlerden bulaşmaktadır. Fekal-oralyayılım gibi diğer bulaş yolları hakkında kanıtlanmış bir bilgi yoktur. Erişkinlere benzer şekilde çocukların ilk başvuru yakınmaları arasında ateş, öksürük, boğaz ağrısı, halsizlik, burun akıntısı vedaha nadiren kusma ve ishal bulunmaktadır. Çocuk hastaların büyük çoğunluğunda asemptomatik ya da hafif klinik seyir izlense de,altta yatan kronik hastalığı olan çocuklarda ağır seyreden olgularbildirilmiştir. SARS-CoV-2’ye karşı özgün bir antiviral tedavi henüzyoktur. Hafif kliniği olan çocuklarda destek tedavi önerilirken, eşlik eden hastalığı olan ya da daha ağır seyir gözlenen çocuklardaönerilen bazı tedaviler vardır. Asemptomatik ya da hafif seyirleenfeksiyonu geçiren çocuk hastalar, riskli ileri yaş grubuna yayılım açısından önemli bir gruptur. Bulaşın engellenmesi, yeni olgusayısının azalması ve sağlık sistemi üzerindeki yükün hafifletilmesiaçısından çok önemlidir. SARS-CoV-2’nin yayılımını engellemekiçin toplum içinde hijyen kurallarına uymak, sosyal mesafeye dikkat etmek ve tanı almış hastaların, aileleri ve temaslı oldukları kişilerin taranması ve izole edilmesi gereklidir.
Anahtar Kelime:

SARS-CoV-2 infection in children

Öz:
SARS-CoV-2, a RNA virus that emerged in December 2019 in the city of Wuhan in China and took hold of the whole world, affects children as well as all age groups. In our country, we started to observe the first cases by March 2020. SARS-CoV-2, which is transmitted by droplets and by way of contact with surfaces contaminated by these droplets, is generally transmitted to children from adults through close contact. There is no proven information about other transmission routes such as fecal-oral transmission. Similar to adults, the primary symptoms at presentation include fever, cough, sore throat, malaise, nasal discharge, and rarely, vomiting and diarrhea in children. Although the majority of pediatric patients are asymptomatic or have a mild clinical course, severe cases have been reported in children with underlying chronic diseases. There is currently no specific antiviral treatment against the SARS-CoV-2 virus. Supportive treatment is recommended in children with a mild course, and some treatments are recommended in children with comorbidities or in children who are observed to have a more severe course. Asymptomatic pediatric patients or pediatric patients who have a mild course constitute an important group in terms of transmission of the infection to the advanced age group who carry high risk. Prevention of infection is very important in terms of reducing new cases and alleviating the load on the healthcare system. In order to prevent transmission of SARS-CoV-2, hygienic rules should be pursued in the community, social distancing should be observed, and the family members and contacts of patients who have been diagnosed should be screened and isolated.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık
  • 1. World Health Organization. WHO Statement Regarding Cluster of Pneumonia Cases in Wuhan, China. Available at: https://www.who.int/china/news/detail/09-01- 2020-who-statement-regarding-cluster-of-pneumonia -cases-in-wuhan-china. Accessed 11 January, 2020.
  • 2. World Health Organization. Novel coronavirus (2019- nCoV): situation report 15. Available at: https://www.who. int/docs/default-source/coronaviruse/situation-reports/20200204-sitrep-15-ncov.pdf?sfvrsn=88fe8ad6_4. Accessed February 5, 2020.
  • 3. World Health Organization. Pneumonia of unknown cause-China. 2020. Available at: https://www.who.int/ csr/don/05-january-2020-pneumonia-of-unkown-causechina/en/.
  • 4. World Health Organization. Novel coronavirus. Available at: http://www.euro.who.int/en/health-topics/healthemergencies/novel-coronavirus-2019-ncov_old.
  • 5. Zhu N, Zhang D, Wang W, et al; China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med 2020; 382: 727-33.
  • 6. Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol 2019; 17: 181–92.
  • 7. Donà D, Minotti C, Costenaro P, Da Dalt L, Giaquinto C. Fecal-Oral Transmission of Sars-Cov-2 in Children: Is it Time to Change Our Approach? Pediatr Infect Dis J. 2020 Apr 16. doi: 10.1097/Inf.0000000000002704. [Epub Ahead of Print].
  • 8. Wei WE, Li Z, Chiew CJ, Yong SE, Toh MP, Lee VJ. Presymptomatic transmission of SARS-CoV-2— Singapore, January 23-March 16, 2020. MMWR Morb Mortal Wkly Rep 2020; 69: 411–5.
  • 9. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020; 579: 270–3.
  • 10. Harmer D, Gilbert M, Borman R, Clark KL. Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme. FEBS Lett 2002; 532: 107–10.
  • 11. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395: 497–506.
  • 12. Sun D, Li H, Lu XX, et al. Clinical features of severe pediatric patients with coronavirus disease 2019 in Wuhan: a single center’s observational study. World J Pediatr 2020 Mar 19. doi: 10.1007/s12519-020-00354-4. [Epub ahead of print].
  • 13. Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis. 2020 Mar 12:ciaa248. doi: 10.1093/cid/ciaa248. [Epub ahead of print].
  • 14. Parri N, Lenge M, Buonsenso D; Coronavirus Infection in Pediatric Emergency Departments (CONFIDENCE) Research Group. Children with Covid-19 in Pediatric Emergency Departments in Italy. N Engl J Med. 2020 May 1:NEJMc2007617. doi: 10.1056/NEJMc2007617. [Epub ahead of print].
  • 15. Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, Tong S. Epidemiology of COVID-19 among children in China. 2020 Mar 16. pii: e20200702. doi: 10.1542/peds.2020-0702. [Epub ahead of print].
  • 16. Robbins E, Ilahi Z, Roth P. Febrile Infant: COVID-19 in Addition to the Usual Suspects. Pediatr Infect Dis J 2020; 39: e81-e82.
  • 17. Zheng F, Liao C, Fan QH, et al. Clinical Characteristics of Children with Coronavirus Disease 2019 in Hubei, China. Curr Med Sci 2020; 40: 275–80.
  • 18. Lu X, Zhang L, Du H, et al. SARS-CoV-2 Infection in Children. N Engl J Med 2020; 382: 1663–5.
  • 19. CDC COVID-19 Response Team. Coronavirus Disease 2019 in Children - United States, February 12-April 2, 2020. MMWR Morb Mortal Wkly Rep 2020; 69: 422–6.
  • 20. Xia W, Shao J, Guo Y, Peng X, Li Z, Hu D. Clinical and CT features in pediatric patients with COVID-19 infection: Different points from adults. Pediatr Pulmonol 2020; 55: 1169–74.
  • 21. Xie X, Chen J, Wang X, Zhang F, Liu Y. Age- and genderrelated difference of ACE2 expression in rat lung. Life Sci 2006; 78: 2166–71.
  • 22. Lee PI, Hu YL, Chen PY, Huang YC, Hsueh PR. Are children less susceptible to COVID-19?. J Microbiol Immunol Infect 2020; 53: 371–2.
  • 23. Ludvigsson JF. Systematic review of COVID-19 in children show milder cases and a better prognosis than adults. Acta Paediatr 2020 Mar 23. doi: 10.1111/apa.15270. [Epub ahead of print].
  • 24. T.C. Sağlık Bakanlığı Halk Sağlığı Genel Müdürlüğü. COVID-19 (SARS-CoV-2 enfeksiyonu) Rehberi, Bilim Kurulu Çalışması. Available at: https://www.tahud.org.tr/ file/ac3d7f7f-752f-4f4f-97d4-3ea943204c8d/COVID-19_Rehberi-6-12.04.2020.pdf. Accessed April 14, 2020.
  • 25. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395: 507–13.
  • 26. Henry BM, de Oliveira MHS, Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med 2020 Apr 10. doi: 10.1515/cclm2020-0369. [Epub ahead of print].
  • 27. Henry BM, Lippi G, Plebani M. Laboratory abnormalities in children with novel coronavirus disease 2019. Clin Chem Lab Med 2020; 58: 1135-8.
  • 28. Wang W, Xu Y, Gao Ret al. Detection of SARS-CoV-2 in Different Types of Clinical Specimens. JAMA. 2020 Mar 11;323(18):1843–4. doi: 10.1001/jama.2020.3786. [Epub ahead of print].
  • 29. Centers for Disease Control and Prevention. Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens from Persons Under Investigation (PUIs) for Coronavirus Disease 2019 (COVID-19). Available at: https://www.cdc.gov/coronavirus/2019-nCoV/lab/guidelines-clinical-specimens.html. Accessed June 10, 2020.
  • 30. Loeffelholz MJ, Tang YW. Laboratory diagnosis of emerging human coronavirus infections - the state of the art. Emerg Microbes Infect 2020; 9: 747–56.
  • 31. Cassaniti I, Novazzi F, Giardina F, et al; Members of the San Matteo Pavia COVID-19 Task Force. Performance of VivaDiag COVID-19 IgM/IgG Rapid Test is inadequate for diagnosis of COVID-19 in acute patients referring to emergency room department. J Med Virol. 2020 Mar 30:10.1002/jmv.25800. doi: 10.1002/jmv.25800. [Epub ahead of print].
  • 32. Diao B, Wen K, Chen J, et al. Diagnosis of Acute Respiratory Syndrome Coronavirus 2 Infection by Detection of Nucleocapsid Protein. Med Rxiv 2020 March 13. doi: https://doi.org/10.1101/2020.03.07.20032524. [Ahead of print].
  • 33. Ai T, Yang Z, Hou H, et al. Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases. Radiology. 2020 Feb 26:200642. doi: 10.1148/radiol.2020200642. [Epub ahead of print].
  • 34. Yang P, Liu P, Li D, Zhao D. Corona Virus Disease 2019, a growing threat to children?. J Infect 2020; 80: P671–93.
  • 35. Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today’s diseases?. Lancet Infect Dis 2003; 3: 722–7.
  • 36. Zhou D, Dai SM, Tong Q. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. J Antimicrob Chemother. 2020 Mar 20:dkaa114. doi: 10.1093/jac/dkaa114. [Epub ahead of print].
  • 37. Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020 Mar 20:105949. doi: 10.1016/j.ijantimicag.2020.105949. [Epub ahead of print].
  • 38. Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 2020; 14: 72–3.
  • 39. Sissoko D, Laouenan C, Folkesson E, et al. Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proofof-Concept Trial in Guinea. PLoS Med 2016; 13: e1001967.
  • 40. Chen C, Huang J, Cheng Z, et al. Favipiravir versus arbidol for COVID-19: a randomized clinical trial. MedRxiv. 2020 April 15. doi: https://doi.org/10.1101/2020.03.17.2003 7432. [Ahead of print].
  • 41. Bouazza N, Treluyer JM, Foissac F, et al. Favipiravir for children with Ebola. Lancet 2015; 385: 603–4.
  • 42. Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. The Lancet 2020; 395: P15569–78.
  • 43. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel CoronavirusInfected Pneumonia in Wuhan, China. JAMA 2020; 323: 1061–9.
  • 44. Cao B, Wang Y, Wen D, et al. A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 2020; 382: 1787–99.
  • 45. Wang Z, Yang B, Li Q, Wen L, Zhang R. Clinical Features of 69 Cases with Coronavirus Disease 2019 in Wuhan, China. Clin Infect Dis. 2020 Mar 16:ciaa272. doi: 10.1093/ cid/ciaa272. [Epub ahead of print].
  • 46. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. The Lancet 2020; 395: 473–5.
  • 47. Bhimraj A, Morgan RL, Shumaker AH, et al. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. Clin Infect Dis. 2020 Apr 27:ciaa478. doi: 10.1093/cid/ciaa478. [Epub ahead of print].
  • 48. Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020; 395: 1033–4.
  • 49. Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A 2020; 117: 10970–5.
  • 50. Shen C, Wang Z, Zhao F, et al. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. JAMA 2020; 323: 1582–9.
  • 51. Cao W, Liu X, Bai T, et al. High-Dose Intravenous Immunoglobulin as a Therapeutic Option for Deteriorating Patients With Coronavirus Disease 2019. Open Forum Infect Dis 2020; 7: ofaa102.
  • 52. van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. N Engl J Med 2020; 382: 1564–7.
  • 53. Cai Y, Wu X, Zhang Y, et al. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Contamination in Air and Environment in Temporary COVID-19 ICU Wards. Research Square. 2020 April 06.doi:10.21203/rs.3.rs-21384/ v1. [Ahead of print].
  • 54. Adams J. Recommendation regarding the use of cloth face coverings, especially in areas of significant community-based transmission. Available at: https://www.cdc. gov/coronavirus/2019-ncov/prevent-getting-sick/clothface-cover.htm. Accessed June 10, 2020.
  • 55. Okamoto K, Rhee Y, Schoeny M, et al. Impact of doffing errors on healthcare worker self-contamination when caring for patients on contact precautions. Infect Control Hosp Epidemiol 2019; 40: 559–65.
APA cokugras H, Önal P (2020). Çocuklarda SARS-CoV-2 enfeksiyonu. , 95 - 102. 10.14744/TurkPediatriArs.2020.20270
Chicago cokugras Haluk Cezmi,Önal Pınar Çocuklarda SARS-CoV-2 enfeksiyonu. (2020): 95 - 102. 10.14744/TurkPediatriArs.2020.20270
MLA cokugras Haluk Cezmi,Önal Pınar Çocuklarda SARS-CoV-2 enfeksiyonu. , 2020, ss.95 - 102. 10.14744/TurkPediatriArs.2020.20270
AMA cokugras H,Önal P Çocuklarda SARS-CoV-2 enfeksiyonu. . 2020; 95 - 102. 10.14744/TurkPediatriArs.2020.20270
Vancouver cokugras H,Önal P Çocuklarda SARS-CoV-2 enfeksiyonu. . 2020; 95 - 102. 10.14744/TurkPediatriArs.2020.20270
IEEE cokugras H,Önal P "Çocuklarda SARS-CoV-2 enfeksiyonu." , ss.95 - 102, 2020. 10.14744/TurkPediatriArs.2020.20270
ISNAD cokugras, Haluk Cezmi - Önal, Pınar. "Çocuklarda SARS-CoV-2 enfeksiyonu". (2020), 95-102. https://doi.org/10.14744/TurkPediatriArs.2020.20270
APA cokugras H, Önal P (2020). Çocuklarda SARS-CoV-2 enfeksiyonu. Türk Pediatri Arşivi, 55(2), 95 - 102. 10.14744/TurkPediatriArs.2020.20270
Chicago cokugras Haluk Cezmi,Önal Pınar Çocuklarda SARS-CoV-2 enfeksiyonu. Türk Pediatri Arşivi 55, no.2 (2020): 95 - 102. 10.14744/TurkPediatriArs.2020.20270
MLA cokugras Haluk Cezmi,Önal Pınar Çocuklarda SARS-CoV-2 enfeksiyonu. Türk Pediatri Arşivi, vol.55, no.2, 2020, ss.95 - 102. 10.14744/TurkPediatriArs.2020.20270
AMA cokugras H,Önal P Çocuklarda SARS-CoV-2 enfeksiyonu. Türk Pediatri Arşivi. 2020; 55(2): 95 - 102. 10.14744/TurkPediatriArs.2020.20270
Vancouver cokugras H,Önal P Çocuklarda SARS-CoV-2 enfeksiyonu. Türk Pediatri Arşivi. 2020; 55(2): 95 - 102. 10.14744/TurkPediatriArs.2020.20270
IEEE cokugras H,Önal P "Çocuklarda SARS-CoV-2 enfeksiyonu." Türk Pediatri Arşivi, 55, ss.95 - 102, 2020. 10.14744/TurkPediatriArs.2020.20270
ISNAD cokugras, Haluk Cezmi - Önal, Pınar. "Çocuklarda SARS-CoV-2 enfeksiyonu". Türk Pediatri Arşivi 55/2 (2020), 95-102. https://doi.org/10.14744/TurkPediatriArs.2020.20270